Liver Transplant Recipients
11
2
2
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (11)
COVID Protection After Transplant-Immunosuppression Reduction
Liver Transplant Recipients and 30-Second Lie-to-Sit Test
Blood Draw Study for Liver Transplant Patients
Effect of TCI Propofol on Liver Transplant (TCI) Propofol on Intra-operative Usage of Vasopressors in Liver Transplant Recipients.
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients
Adult Liver Transplant Enhanced Care
Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients
Pharmacokinetic Studies of Tacrolimus in Transplant Patients
L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients
The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant